VIP: Vasoactive Intestinal Peptide Research Monograph

Overview

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide that was first isolated from porcine duodenal tissue in 1970 by Sami Said and Viktor Mutt. Originally identified for its potent vasodilatory properties, VIP has since been recognized as one of the most versatile signaling molecules in mammalian physiology, with established roles in vasodilation, smooth muscle relaxation, immune regulation, neuroprotection, circadian rhythm maintenance, and respiratory function. The breadth of its biological activities is matched by few other endogenous peptides, making VIP a molecule of extraordinary physiological importance and research interest.

VIP has a molecular weight of 3326.83 g/mol and belongs to the glucagon-secretin superfamily of peptides, sharing structural homology with pituitary adenylate cyclase-activating polypeptide (PACAP), secretin, and glucagon. In the body, VIP is widely distributed across the central and peripheral nervous systems, gastrointestinal tract, respiratory epithelium, and immune tissues. It functions as both a neurotransmitter and a paracrine signaling molecule, exerting its effects through two specific G-protein-coupled receptors: VPAC1 and VPAC2. The widespread distribution of VIP-expressing neurons and the ubiquitous expression of its receptors underlie the peptide’s remarkably diverse physiological roles.

The discovery of VIP initiated an entirely new chapter in gastrointestinal and neuropeptide physiology. Over the subsequent five decades, research has revealed that VIP’s initial characterization as a vasodilator vastly underestimated its biological significance. The peptide is now understood to be a central mediator of neuroimmune communication, a critical component of the circadian clock, a potent endogenous anti-inflammatory agent, and an essential regulator of pulmonary vascular tone. Its C-terminal amidation is critical for full biological activity, as deamidated VIP shows substantially reduced receptor binding and biological potency.

Mechanism of Action

VIP signals through VPAC1 and VPAC2 receptors, which couple primarily to Gs proteins to activate adenylyl cyclase and increase intracellular cAMP. The widespread expression of these receptors across multiple organ systems accounts for VIP’s remarkably diverse physiological effects. Understanding the receptor biology is essential for interpreting VIP’s context-dependent actions.

VPAC1 and VPAC2 Receptor Signaling

VPAC1 is predominantly expressed in the lungs, liver, intestinal epithelium, and T lymphocytes, while VPAC2 is more highly expressed in the central nervous system (particularly the suprachiasmatic nucleus), smooth muscle, and pancreas. Both receptors activate Gs-mediated cAMP production, but they also engage additional signaling cascades including phospholipase C (PLC), protein kinase C (PKC), and mitogen-activated protein kinase (MAPK) pathways depending on the cellular context and receptor density.

The differential tissue distribution of VPAC1 and VPAC2 enables VIP to produce tissue-specific effects. In immune cells, VPAC1 signaling predominates and drives anti-inflammatory responses through cAMP-mediated suppression of NF-kB and activation of CREB-dependent anti-inflammatory gene expression. In the suprachiasmatic nucleus, VPAC2 signaling is critical for circadian pacemaker function and intercellular synchronization. In vascular smooth muscle, both receptors contribute to vasodilation through cAMP-mediated relaxation of contractile elements.

Vasodilation and Smooth Muscle Relaxation

VIP is one of the most potent endogenous vasodilators. It induces vascular smooth muscle relaxation through cAMP-dependent inhibition of myosin light chain kinase (MLCK), leading to decreased vascular tone and increased blood flow. In the pulmonary vasculature, VIP acts as a key regulator of pulmonary arterial pressure, and its deficiency has been implicated in pulmonary hypertension. Studies have demonstrated that VIP expression is markedly reduced in the pulmonary arteries of patients with idiopathic pulmonary arterial hypertension compared to healthy controls, and that VIP administration can reduce pulmonary artery pressure and improve cardiac output.

Beyond vascular smooth muscle, VIP relaxes bronchial, gastrointestinal, and urogenital smooth muscle. In the airways, VIP functions as the primary non-adrenergic, non-cholinergic (NANC) bronchodilator, counterbalancing the bronchoconstricting effects of acetylcholine and substance P. This bronchodilatory role is particularly important in the regulation of airway caliber and the pathophysiology of asthma and chronic obstructive pulmonary disease.

Immune Modulation

VIP exerts potent anti-inflammatory and immunomodulatory effects through VPAC1 signaling on immune cells. The anti-inflammatory actions of VIP are among the most extensively characterized of any endogenous neuropeptide and include promotion of a Th2-biased immune response, inhibition of pro-inflammatory cytokine production from activated macrophages, induction of regulatory T-cell differentiation, and generation of tolerogenic dendritic cells. Through these complementary mechanisms, VIP functions as a critical mediator of neuroimmune communication that maintains immune homeostasis and prevents excessive inflammatory damage.

Neuroprotective Mechanisms

VIP promotes neuronal survival through multiple cAMP-dependent pathways, including activation of protein kinase A (PKA), Akt/PKB, and CREB-mediated transcription of pro-survival genes such as Bcl-2. In addition, VIP enhances the release of neurotrophic factors including brain-derived neurotrophic factor (BDNF) and activity-dependent neuroprotective protein (ADNP) from glial cells, providing indirect neuroprotective support through paracrine mechanisms.

Pharmacokinetics

VIP is a 28-amino acid peptide with a molecular weight of 3326.83 g/mol, and its pharmacokinetic profile reflects the challenges common to peptide therapeutics of this size. The peptide has a notably short plasma half-life, estimated at 1 to 2 minutes following intravenous administration. This rapid clearance is attributable to extensive proteolytic degradation by circulating peptidases, including dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase (NEP), as well as rapid hepatic and pulmonary extraction.

The short circulating half-life of VIP has been a major challenge in translating its biological activities into clinical therapeutics. Following intravenous injection, VIP is rapidly distributed and eliminated, necessitating continuous infusion or alternative delivery strategies to maintain effective plasma concentrations. Subcutaneous administration provides somewhat extended absorption but does not fundamentally alter the peptide’s susceptibility to proteolytic degradation once it reaches the systemic circulation.

Alternative delivery routes have been explored to circumvent the rapid systemic degradation. Intranasal administration has been investigated extensively in the context of CIRS and respiratory applications, leveraging the nasal mucosa for both local delivery to the respiratory tract and potential absorption across the olfactory epithelium for CNS access. Inhaled aerosolized VIP has been studied for pulmonary applications, achieving high local concentrations in the lungs while minimizing systemic exposure and the associated hypotensive effects.

Distribution of VIP following systemic administration reflects its receptor distribution, with significant uptake in the lungs (which contain both VPAC1 and VPAC2 receptors), gastrointestinal tract, and nervous system. The peptide does not readily cross the blood-brain barrier under normal conditions, though receptor-mediated transport mechanisms may facilitate limited CNS access. Aviptadil, the synthetic form of VIP used in clinical investigations, shares the same pharmacokinetic properties and has been studied in formulations designed to prolong its biological availability.

Research Applications

Immune Regulation and Autoimmunity

VIP has been extensively studied as an endogenous anti-inflammatory agent with demonstrated applications in multiple autoimmune disease models:

• Th1/Th2 balance: VIP promotes a shift from pro-inflammatory Th1 responses toward anti-inflammatory Th2 responses, reducing IFN-gamma and IL-2 production while increasing IL-4 and IL-10 output
• Macrophage modulation: VIP inhibits lipopolysaccharide (LPS)-induced production of TNF-alpha, IL-6, IL-12, and nitric oxide in activated macrophages through cAMP-mediated suppression of NF-kB
• Regulatory T-cell induction: VIP promotes the differentiation and expansion of CD4+CD25+FoxP3+ regulatory T cells, which suppress autoimmune responses and maintain peripheral tolerance
• Tolerogenic dendritic cells: VIP treatment generates dendritic cells with a tolerogenic phenotype capable of inducing antigen-specific regulatory T cells, a mechanism with potential applications in autoimmune disease and transplant tolerance
• Autoimmune disease models: VIP administration ameliorated disease in animal models of rheumatoid arthritis, experimental autoimmune encephalomyelitis (EAE), and inflammatory bowel disease, reducing clinical scores and histopathological damage

Circadian Rhythm Research

VIP plays a critical role in the master circadian pacemaker located in the suprachiasmatic nucleus (SCN) of the hypothalamus. VPAC2 receptors are abundantly expressed in SCN neurons, and VIP signaling is essential for synchronizing individual neuronal oscillators into a coherent circadian rhythm:

• SCN intercellular coupling: VIP released from a subset of SCN neurons acts on VPAC2 receptors on neighboring neurons, coupling their circadian oscillations and maintaining the synchronized rhythmic output necessary for coherent behavioral and physiological rhythms
• Clock gene regulation: VIP/VPAC2 signaling modulates the expression of core clock genes including Per1, Per2, and Cry1 through cAMP/CREB-mediated transcription
• Light entrainment: VIP-expressing neurons receive direct retinal input through the retinohypothalamic tract and relay photic information to synchronize the circadian clock with the environmental light-dark cycle
• Circadian disruption models: VIP-deficient mice exhibit severely disrupted circadian rhythms, demonstrating the peptide’s essential role in biological timekeeping

Respiratory and Pulmonary Research

VIP has been investigated extensively for its role in respiratory physiology and pulmonary vascular regulation:

• Pulmonary hypertension: Studies demonstrated reduced VIP expression in pulmonary arteries of patients with primary pulmonary hypertension, and VIP administration reduced pulmonary artery pressure and improved hemodynamic parameters in clinical investigations
• Bronchodilation: VIP serves as the primary NANC inhibitory neurotransmitter in the airways, providing endogenous bronchodilatory tone
• CIRS/biotoxin illness: VIP has been investigated extensively in the context of chronic inflammatory response syndrome (CIRS) and mold-related illness, where dysregulated VIP levels have been reported and VIP replacement has been studied as a therapeutic intervention
• Lung surfactant: VIP has been shown to stimulate surfactant production by type II alveolar cells, contributing to lung compliance and protection
• ARDS: Aviptadil (synthetic VIP) has been investigated in clinical trials for acute respiratory distress syndrome, with reported improvements in oxygenation and survival in preliminary studies

Neuroprotection

VIP has demonstrated neuroprotective properties in multiple experimental paradigms, including protection against excitotoxicity, oxidative stress, and beta-amyloid neurotoxicity. VIP signaling through VPAC receptors in the brain promotes neuronal survival through cAMP-dependent activation of pro-survival kinases including PKA and Akt, and through enhanced expression of neurotrophic factors. These properties have made VIP a subject of investigation in models of Alzheimer’s disease, Parkinson’s disease, and stroke.

Safety Profile

VIP has been studied in human subjects in multiple clinical contexts, and its safety profile is generally well characterized:

• Hemodynamic effects: The most significant pharmacological effect of systemic VIP administration is vasodilation, which can produce dose-dependent reductions in blood pressure and compensatory tachycardia. This vasodilatory effect is the primary dose-limiting factor in systemic administration and requires careful hemodynamic monitoring in clinical research settings
• Gastrointestinal effects: VIP can produce dose-dependent gastrointestinal effects including increased intestinal secretion, which may manifest as loose stools or diarrhea at higher doses
• Facial flushing: Transient facial flushing is commonly reported following systemic VIP administration, consistent with its vasodilatory properties
• Local delivery well tolerated: Inhaled and intranasal VIP delivery routes have been generally well tolerated, with minimal systemic side effects due to limited systemic absorption
• No immunosuppression: Despite potent anti-inflammatory properties, VIP does not appear to cause generalized immunosuppression. Its mechanism involves immune modulation (shifting Th1/Th2 balance and inducing regulatory T cells) rather than broad immune suppression
• Short duration of effects: The short plasma half-life of VIP (1-2 minutes) means that adverse effects are typically transient and self-limiting following discontinuation of administration

Dosing in Research

Molecular Properties

Storage and Handling for Research

VIP should be stored as a lyophilized powder at -20°C for long-term stability. As a 28-amino acid peptide containing methionine (susceptible to oxidation), proper storage conditions are critical for maintaining bioactivity. Under recommended conditions, lyophilized VIP is stable for 12 months or longer. Once reconstituted with bacteriostatic water or sterile water, solutions should be stored at 2-8°C, protected from light, and used within 14-21 days. The methionine residue at position 17 is particularly susceptible to oxidative degradation, which can significantly reduce biological activity.

Current Research Landscape

VIP remains one of the most actively studied neuropeptides in biomedical research, with applications spanning immunology, pulmonary medicine, neuroscience, and chronobiology. Key areas of ongoing investigation include:

1. CIRS and biotoxin illness: Research into VIP’s role in chronic inflammatory response syndrome and its potential as both a biomarker and therapeutic target in mold-related illness continues, with particular focus on intranasal delivery protocols and combinatorial approaches with other immune-modulatory interventions.

2. Pulmonary applications: Continued investigation of VIP and aviptadil in pulmonary hypertension, ARDS, and other respiratory conditions. The COVID-19 pandemic renewed interest in VIP for acute respiratory failure, with aviptadil investigated in clinical trials for severe SARS-CoV-2-associated ARDS.

3. Autoimmune therapies: Development of VIP-based approaches for rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease, including VIP-loaded nanoparticle delivery systems and tolerogenic dendritic cell-based immunotherapy protocols.

4. Circadian medicine: Understanding VIP’s role in circadian disruption associated with shift work, jet lag, and metabolic disease, with potential applications in restoring disrupted circadian rhythms through targeted VIP signaling modulation.

5. Neuroprotective strategies: Research into VIP analogs with improved stability and blood-brain barrier penetration for neurodegenerative disease applications, building on demonstrated neuroprotection in preclinical models of Alzheimer’s and Parkinson’s disease.

6. Stable analog development: Engineering of VIP analogs with enhanced resistance to proteolytic degradation, improved receptor selectivity, and extended duration of action to overcome the limitations imposed by VIP’s extremely short plasma half-life.

References

The studies referenced throughout this monograph represent a selection of the published literature on Vasoactive Intestinal Peptide. VIP research spans over five decades and encompasses thousands of published studies across multiple disciplines. For a comprehensive bibliography, researchers are encouraged to search PubMed and Google Scholar using the terms “vasoactive intestinal peptide,” “VIP neuropeptide,” or “VPAC receptor” for the most current publications.